甲状腺相关眼病预后因素及治疗的研究进展

Current progress of prognostic factors and treatment for thyroid-associated ophthalmopathy

甲状腺相关眼病(TAO),又称Graves眼病,是Graves病最常见、最复杂的甲状腺以外受累的器官病变,影响其发生发展的因素很多,遗传、环境等因素均影响患者预后。目前其发病机制尚不明确,也无针对病因的有效治疗方法,临床常用的有药物治疗、球后放疗、手术治疗等多种治疗方式。近年来免疫治疗取得重大进展,为TAO的治疗提供了新的选择。现就TAO治疗及预后因素的最新进展作一综述。

Thyroid-associated ophthalmopathy(TAO),also known as Graves ophthalmopathy,is the most common and complex organ lesion of Graves disease with non-thyroid involvement.There are many factors affecting its occurrence and development,including genetic and environmental factors,which affect the prognosis of patients.At present,the pathogenesis of the disease is not clear,and there is no effective therapy for the cause of the disease.The commonly used clinical treatment methods include drug therapy,orbital radiotherapy,surgical treatment and so on.With the great progress of immunotherapy in recent years,it provides a new option for TAO treatment.We will give a review on the prognostic factors and the latest progress in the treatment of TAO in this article.